Research Summary

Dr. Chiung-Yu Huang is Professor of Biostatistics at the Department of Epidemiology and Biostatistics and an elected Fellow of the American Statistical Association (ASA). She is a Member of the UCSF Helen Diller Family Comprehensive Cancer Center and an Adjunct Professor at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center. She is recognized for her novel methodology research in survival analysis, competing risks analysis, recurrent event analysis, outcome-dependent sampling, and design and evaluation of vaccine efficacy trials. Dr. Huang’s recent methodology contributions include (1) methods for combining information from external large databases, such as disease registries, to improve efficiency in the analysis of relatively small-scale studies that collect more detailed patient-level information. The importance of such methods has been recognized as we have now entered the big data era; (2) methods to better model, estimate, and predict the risk of recurrent events to identify individuals who are at a high risk of experiencing recurrent events, allowing one to target these individuals for more intensive monitoring and treatment; (3) statistical methods for analyzing vaccine trials with active or passive surveillance by incorporating information about infecting pathogens collected at the time of infection; (4) efficient statistical methods for survival data collected in prevalent cohort studies. (5) benefit-risk assessment tools for evaluating treatment risks and benefit in cancer patients with end-stage disease; (6) statistical methods that can properly account for informative clinic visits in the analysis of electronic health records.

In addition to statistical method research, Dr. Huang has a rich experience in collaborative research across a wide range of areas, including influenza, malaria, transplant, and cancer studies. During her service as a Mathematical Statistician at NIAID, NIH (2004-2013), she worked closely with both extramural and intramural NIH scientists on the design, conduct, monitoring, analysis, and presentation of preclinical and clinical studies. She served as a statistician to the NIAID Influenza Research Collaboration (NIRC) and the Mexican Emerging Infectious Disease Clinical Research Network (La Red), and was a statistical reviewer to the Infectious Disease Clinical Research Program (IDCRP) and several intramural laboratories within NIAID. She has received numerous awards for her collaborative research, including the prestigious NIAID Merit Award. Prior to joining UCSF, she was an Associate Professor at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center (2013-2017), where she served as the lead statistician to the Breast and Ovarian Cancer Program. She also worked closely with the Transplant and Oncology Infectious Diseases Programs in modeling and characterizing morbidities attributable to infections occurring after solid organ transplants (SOT) and hematopoietic stem cell transplants (HSCT). Since joining UCSF in 2017, she has been serving as the lead statistician to the Hematopoietic Malignancies Program at UCSF Helen Diller Family Comprehensive Cancer Center and is the primary statistician to the University of California Hematologic Malignancies Consortium (UCHMC).

Research Funding

  • July 1, 2015 - June 30, 2020 - Reprogramming the pancreatic tumor microenvironment with immunotherapy, Statistician/Principal Investigator (Subaward). Sponsor: NIH/NCI, Sponsor Award ID: R01CA197296
  • July 1, 2015 - June 30, 2020 - Statistical Methods for Survival and Recurrent Event Data in Clinical Research, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA193888
  • September 1, 2017 - December 31, 2018 - Comparing Patient Centered Outcomes in the Management of Pain between Emergency Departments and Dedicated Acute Care Facilities for Adults with Sickle Cell disease, Statistician/Principal Investigator (Subaward). Sponsor: PCORI, Sponsor Award ID: HIS-1403-11888
  • July 1, 2015 - June 30, 2020 - Reprogramming the pancreatic tumor microenvironment with immunotherapy, Statistician/Principal Investigator (Subaward). Sponsor: NIH/NCI, Sponsor Award ID: R01CA197296

Education

National Tsing-Hua University, Hsinchu, Taiwan, B.S., 07/1994, Mathematics
National Tsing-Hua University, Hsinchu, Taiwan, M.S., 07/1996, Mathematics
Johns Hopkins University, Baltimore, Maryland, Ph.D., 05/2002, Biostatistics

Honors & Awards

  • 1991
    Invited Contestant, Asian Pacific Mathematics Olympiad (APMO)
  • 1991
    College admission for gifted students under Taiwan’s Special Education Act
  • 1991-1995
    Four-Year College Scholarship for Gifted Students in Mathematics and Sciences, Taiwanese Ministry of Education
  • 1992, 1993, 1994
    President’s Academic Awards (3 times), National Tsing-Hua University
  • 1994
    Graduated first in class from the Department of Mathematics, National Tsing-Hua University, Taiwan (completed a bachelor's degree in three years and admitted into graduate school without entrance exam)
  • 1997-2002
    Five-year departmental scholarship, Department of Biostatistics, Johns Hopkins University
  • 2002
    Margaret Merrell Award for Excellence in Research, Department of Biostatistics, Johns Hopkins University
  • 2004
    NIH Travel Award, ENAR Young Investigators Meeting
  • 2003-2005
    Grant-in-Aid of Research, Artistry, and Scholarship, University of Minnesota
  • 2005
    Performance Award for special achievement, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH
  • 2005, 2006, 2007, 2008, 2010, 2011
    Special Act or Service Award, National Institute of Allergy and Infectious Diseases, NIH
  • 2007
    NIAID Merit Award, National Institute of Allergy and Infectious Diseases, NIH

Selected Publications

  1. Sun Y, McCulloch CE, Marr KA, Huang CY. Recurrent events analysis with data collected at informative clinical visits in electronic health records. Journal of the American Statistical Association. 2021; 116(534):594-604.  View on PubMed
  2. Sun Y, Chiou SH, Marr KA, Huang CY. Statistical inference on shape- and size-indexes for counting processes. Biometrika. 2021.  View on PubMed
  3. Ma H, Peng L, Huang CY, Fu H. Heterogeneous individual risk modelling of recurrent events. Biometrika. 2021; 108(1):183-198.  View on PubMed
  4. Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf J, Martin TG, Shah ND, Wong SW. Macrophage activation syndrome-like manifestations (MAS-L) following BCMA-directed CAR T-cells in multiple myeloma. Blood Advances. 2021.  View on PubMed
  5. Lanzkron S, Little J, Wang H, Field JJ, Shows JR, Haywood C,Mustapha Saheed M, Proudford M, Robertson D, Kincaid A, Burgess L, Green C, Seufert R, Brooks J, Piehet A, Griffin B, Arnold N, Frymark S, Wallace M, Abu Al Hamayel N, Huang CY, Segal J, Varadhan R. Treatment of acute pain in adults with sickle cell disease in an infusion center versus the emergency department: a multicenter prospective cohort study. Annals of Internal Medicine. 2021.  View on PubMed
  6. Maheshwari JA, Kolaitis NA, Anderson MR, Benvenuto L, Gao Y, Katz PP, Greenland J, Wolters PJ, Covinsky K, Hays SR, Kukreja J, Calabrese DR, Venado A, Shah RJ, Leard LE, Trinh B, Huang CY, Glidden D, Kleinhenz ME, Golden JA, Sutter N, Tietje-Ulrich G, Criner RN, Arcasoy SM, Christie JD, Diamond J, Singer JP. Construct and Predictive Validity of Sarcopenia in Lung Transplant Candidates. Ann Am Thorac Soc. 2021 Sep; 18(9):1464-1474.  View on PubMed
  7. Moksud N, Loo LWM, Yang J, Huang CY, Haiman C, Le Marchand L, Wilkens L, Cheng I. Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study. Breast Cancer Research and Treatment. 2021.  View on PubMed
  8. Wong SW, Shah N, Ledergor G, Martin T, Wolf J, Shui AM, Huang CY, Martinez-Lope J. Early dynamics of response correlate with progression-free survival in multiple myeloma patients treated with BCMA CAR-T cells. Frontiers in Immunology. 2021.  View on PubMed
  9. Tam A, Jung Y, Young R, Huang CY, Wolf J, Shah N, Martin T, Wong S, Lo M. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. Journal of Oncology Pharmacy Practice. 2021.  View on PubMed
  10. Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Martin T, Wolf J, Shah N, Wong SW. Infectious complications in relapsed refractory multiple myeloma patients after BCMA CAR T therapy. Blood Advances. 2021.  View on PubMed
  11. Lyu T, Luo X, Huang CY, Sun Y. Additive rates model for recurrent event data with intermittently observed time-dependent covariates. Stat Methods Med Res. 2021 Aug 26; 9622802211027593.  View on PubMed
  12. Sheng Y, Sun Y, Huang CY, Kim MO. Synthesizing external aggregated information in the penalized Cox regression under population heterogeneity. Stat Med. 2021 Jun 16.  View on PubMed
  13. Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol. 2021 Jul 10; 39(20):2247-2256.  View on PubMed
  14. Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021 Jun 01; 127(11):1816-1826.  View on PubMed
  15. Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy VE, Arora S, Wolf JL, Martin TG, Wong SW, Shah N. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021 06; 27(6):477.e1-477.e7.  View on PubMed
  16. Wadhwani SI, Huang CY, Gottlieb L, Beck AF, Bucuvalas J, Kotagal U, Lyles C, Lai JC. Center variation in long-term outcomes for socioeconomically deprived children. Am J Transplant. 2021 Sep; 21(9):3123-3132.  View on PubMed
  17. Sheng Y, Sun Y, Huang CY, Kim MO. Synthesizing external aggregated information in the presence of population heterogeneity: A penalized empirical likelihood approach. Biometrics. 2021 Feb 02.  View on PubMed
  18. Sugidono M, Lo M, Young R, Rosario K, Jung Y, Huang CY, Sheng Y, Huang LW, Olin RL. Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults. Transplant Cell Ther. 2021 04; 27(4):344.e1-344.e5.  View on PubMed
  19. Tymofiyeva O, Henje E, Yuan JP, Huang CY, Connolly CG, Ho TC, Bhandari S, Parks KC, Sipes BS, Yang TT, Xu D. Reduced anxiety and changes in amygdala network properties in adolescents with training for awareness, resilience, and action (TARA). Neuroimage Clin. 2021; 29:102521.  View on PubMed
  20. Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):246-256.e2.  View on PubMed

Go to UCSF Profiles, powered by CTSI